Tonix Pharmaceuticals, Inc.

219 articles with Tonix Pharmaceuticals, Inc.

• Tonix Pharmaceuticals Prices $9.0 Million Public Offering

  11/15/2019

  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today the pricing of an underwritten public offering with expected total gross proceeds of $9.0 million before deducting underwriting discounts, commissions and other offering expenses payable by the Company.

• Tonix Pharmaceuticals Reports Third Quarter 2019 Financial Results and Operational Highlights

  11/8/2019

  Tonix Pharmaceuticals Holding Corp., a clinical-stage biopharmaceutical company, announced financial results for the quarter ended September 30, 2019, and provided an overview of recent operational highlights.

• Tonix Pharmaceuticals Announces 12-Week Primary Endpoint and Addition of Adaptive Design Features in the Currently-Enrolling Phase 3 RECOVERY Study of Tonmya® for PTSD, Following FDA Meeting

  11/4/2019

  Tonix Pharmaceuticals Holding Corp. announced that in the currently-enrolling Phase 3 study of Tonmya®* for the treatment of posttraumatic stress disorder, the timing of the primary endpoint analysis has been changed from Week 4 to Week 12 and the Company plans to add an interim analysis that allows for a potential sample size adjustment, based on guidance from its recent Breakthrough Therapy Type B Clinical Guidance meeting with the U.S. Food and Drug Administration.

• Tonix Pharmaceuticals Announces 1-for-10 Reverse Stock Split

  10/31/2019

  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, announced today that it will effect a 1-for-10 reverse stock split of its outstanding common stock.

• Tonix Pharmaceuticals Announces Issuance of U.S. Patent for Crystalline Tianeptine Oxalate Salt, the Active Ingredient of TNX-601

  10/23/2019

  Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the U.S. Patent and Trademark Office ("USPTO") issued U.S. Patent No. 10,449,203 to the Company on October 22, 2019.

• Tonix Pharmaceuticals Joins the Alliance for Biosecurity

  10/15/2019

  Tonix Pharmaceuticals Holding Corp. announced that it has joined the Alliance for Biosecurity The Alliance is a coalition of biopharmaceutical companies and laboratory/academic partners that promotes a strong public-private partnership to ensure medical countermeasures are available to protect public health and enhance national health security.

• Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting

  10/31/2018

  New Phase 3 Trial of Tonmya® for the treatment of PTSD to Commence First Quarter 2019

• 

  After Trial Failure, Tonix Sees Glimmer of Hope for Future of PTSD Drug

  8/22/2018

  Shares of Tonix Pharmaceuticals shot up 25 percent in premarket trading this morning after the company announced there may be a future for its late-stage posttraumatic stress disorder treatment Tonmya after a Phase III trial was halted early in July following a data review showed an inadequate re...
• 

  Tonix Pharma Halts Phase III Trial for PTSD

  7/27/2018

  Tonix Pharmaceuticals is halting its Phase III clinical trial of Tonmya in military related posttraumatic stress disorder (PTSD).

• Tonix Pharmaceuticals Appoints David L. Grange to the Board of Directors

  2/15/2018

  Gen. Grange assumes the seat held by Stuart Davidson, who has stepped down from the position of company director that Mr. Davidson has held since 2011.

• Tonix Pharmaceuticals Receives Notice of Allowance for New U.S. Patent for the Active Ingredient in Tonmya (Cyclobenzaprine HCl Sublingual Tablets)

  1/23/2018

  Tonix is in Phase 3 development of Tonmya, a FDA-designated Breakthrough Therapy for the treatment of PTSD.

• Tonix Pharmaceuticals Announces Publication Reporting Synthesis, Construction and Characterization of a Potential Smallpox-Preventing Vaccine Candidate TNX-801 (Live Horsepox Virus From Cell Culture)

  1/22/2018

  The research was conducted in conjunction with scientists from the University of Alberta, a leading Canadian research university.

• Tonix Pharmaceuticals Appoints Jessica Morris as COO

  1/9/2018

  Ms. Morris brings to the senior leadership team a deep understanding of drug development and corporate strategy from her tenure at Tonix as well as over a decade of experience in the financial industry.

• Tonix Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Programs Update

  11/7/2017

  At September 30, 2017, Tonix had cash and cash equivalents of $29.3 million. Net cash used in operating activities for the third quarter was $5.0 million.

• Tonix Pharmaceuticals Reports Outcomes From U.S. FDA Breakthrough Therapy CMC Guidance Meeting of Tonmya (Cyclobenzaprine HCI Sublingual Tablets) for PTSD

  10/17/2017

  Tonix is in Phase 3 development of Tonmya, an FDA-designated Breakthrough Therapy for the treatment of PTSD.

• Tonix Pharma Receives European Patent For The Active Ingredient In Tonmya (Cyclobenzaprine HCL Sublingual Tablets)

  9/15/2017

• Tonix Pharma Elects Margaret Smith Bell To The Board Of Directors

  9/14/2017

• Tonix Pharma Presented Additional Phase II Clinical Results In Military-Related PTSD And Design Of Ongoing Phase III Trial At The 2017 Military Health System Research Symposium

  8/30/2017

• Tonix Pharma To Present Additional Phase II Clinical Results And Design Of Ongoing Phase III Trial In Military-Related PTSD At The 2017 Military Health System Research Symposium

  8/21/2017

• Tonix Pharma Announces Conditional Acceptance Of Tonmya As Proposed Brand Name For TNX-102 SL (Cyclobenzaprine HCL Sublingual Tablets) For The Treatment Of PTSD

  7/6/2017